hrcak mascot   Srce   HID

Pregledni rad
https://doi.org/10.2478/v10007-010-0039-2

Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses

SEPTIMIU BUCURESCU   ORCID icon orcid.org/0000-0002-5333-9361 ; “Rhoen Klinikum AG” Hospital, 97616 Bad Neustadt ad Saale, Germany

Puni tekst: engleski, pdf (59 KB) str. 407-413 preuzimanja: 275* citiraj
APA 6th Edition
BUCURESCU, S. (2010). Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses. Acta Pharmaceutica, 60 (4), 407-413. https://doi.org/10.2478/v10007-010-0039-2
MLA 8th Edition
BUCURESCU, SEPTIMIU. "Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses." Acta Pharmaceutica, vol. 60, br. 4, 2010, str. 407-413. https://doi.org/10.2478/v10007-010-0039-2. Citirano 26.08.2019.
Chicago 17th Edition
BUCURESCU, SEPTIMIU. "Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses." Acta Pharmaceutica 60, br. 4 (2010): 407-413. https://doi.org/10.2478/v10007-010-0039-2
Harvard
BUCURESCU, S. (2010). 'Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses', Acta Pharmaceutica, 60(4), str. 407-413. https://doi.org/10.2478/v10007-010-0039-2
Vancouver
BUCURESCU S. Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses. Acta Pharm. [Internet]. 2010 [pristupljeno 26.08.2019.];60(4):407-413. https://doi.org/10.2478/v10007-010-0039-2
IEEE
S. BUCURESCU, "Development of a selective biopharmaceutical from Herpes simplex virus type 1 glycoproteins E and I for blocking antibody mediated neutralization of oncolytic viruses", Acta Pharmaceutica, vol.60, br. 4, str. 407-413, 2010. [Online]. https://doi.org/10.2478/v10007-010-0039-2

Sažetak
Future cancer therapies will be molecular cures. They will correct, block or destroy cancer cells by targeting molecular changes that lead to carcinogenesis. Destroying cancer cells can be done using oncolytic viruses. By blocking antibody mediated neutralization of oncolytic viruses, Herpes simplex virus type 1 glycoproteins E and I could be used in the adjuvant treatment of cancer for improving the chances of oncolytic viruses to kill cancer cells in vivo.

Ključne riječi
cancer therapies; Herpes simplex virus type 1 glycoproteins E and I; antibody mediated neutralization of oncolytic viruses

Hrčak ID: 59808

URI
https://hrcak.srce.hr/59808

[hrvatski]

Posjeta: 500 *